Stock VIRO VIROGATES A/S
Add to a list
To use this feature you must be a member
Log inSign up

ViroGates A/S Stock

Equities

VIRO

DK0061030574

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:59:52 2024-04-26 EDT 		5-day change 1st Jan Change
6.5 DKK -11.92% Intraday chart for ViroGates A/S +8.33% +7.97%
04-15 Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration CI
03-21 ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 15.2M 2.18M 2.98M Sales 2023 6.99M 1M 1.37M Capitalization 38.81M 5.57M 7.6M
Net income 2022 -9M -1.29M -1.76M Net income 2023 -12M -1.72M -2.35M EV / Sales 2022 8.18 x
Net cash position 2022 9.88M 1.42M 1.94M Net cash position 2023 10.73M 1.54M 2.1M EV / Sales 2023 4.02 x
P/E ratio 2022
-13.5 x
P/E ratio 2023
-1.72 x
Employees 10
Yield 2022 *
-
Yield 2023
-
Free-Float 72.75%
More Fundamentals * Assessed data

Chart ViroGates A/S

Dynamic Chart

Latest news about ViroGates A/S

Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration CI
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ViroGates A/S Provides Earnings Guidance for the Year 2024 CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Virogates Provides Earnings Guidance for 2023 CI
ViroGates A/S Announces an Agreement with Sobi for the Development of Suparnostic® CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ViroGates A/S Announces the Commercial Launch of suPARnostic POC+ Product CI
ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms CI
Denmark's ViroGates Names New CFO MT
ViroGates A/S Announces Chief Financial Officer Changes CI
ViroGates A/S Revises Earnings Guidance for Full-Year 2022 and 2023 CI
ViroGates A/S Announces Executive Changes CI
More news

Press releases ViroGates A/S

Resolutions from the Annual General Meeting of ViroGates A/S AQ
ViroGates announces the outcome of its Q-Submission filing for suPARnostic® TurbiLatex with the US FDA and the overall timeline for filing a submission of a 510k/“De Novo” application with the FDA AQ
ViroGates gives notice to convene the Annual General Meeting on 25 April 2024 AQ
ViroGates announces its Annual Report 2023: Revenue was affected by the loss of COVID-19 customers and a difficult transition into general triage AQ
Subscription of shares by majority shareholder in relation to the recently completed rights emission in ViroGates A/S AQ
More press releases

Quotes and Performance

1 day-11.92%
1 week+8.33%
3 months-20.73%
6 months-66.23%
Current year+7.97%
More quotes

Highs and lows

1 week
5.66
Extreme 5.66
7.38
1 month
5.32
Extreme 5.32
7.46
Current year
5.32
Extreme 5.32
9.14
1 year
4.98
Extreme 4.98
25.30
3 years
4.98
Extreme 4.98
252.00
5 years
4.98
Extreme 4.98
252.00
10 years
4.98
Extreme 4.98
252.00
More quotes

Managers and Directors - ViroGates A/S

Managers TitleAgeSince
Jesper Eugen-Olsen FOU
 Founder 61 00-12-31
Jakob Knudsen CEO
 Chief Executive Officer 56 11-03-31
Josephine Baum Jørgensen DFI
 Director of Finance/CFO 33 23-02-28
Members of the board TitleAgeSince
Lars Krogsgaard BRD
 Director/Board Member 57 16-03-31
Patrik Olof Dahlén CHM
 Chairman 62 22-03-31
Lars Kongsbak BRD
 Director/Board Member 63 15-01-31
More insiders

Quotes

Date Price Change Volume
24-04-26 6.5 -11.92% 424
24-04-25 7.38 +7.27% 150
24-04-24 6.88 +6.17% 103
24-04-23 6.48 +8.91% 5,417
24-04-22 5.95 -0.83% 131,926

Delayed Quote Nasdaq Copenhagen, April 26, 2024 at 10:59 am

More quotes

Company Profile

ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
Sector
Biotechnology & Medical Research
Calendar
2024-05-01 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

1st Jan change Capi.
VIROGATES A/S Stock ViroGates A/S
+7.97% 6M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 377M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. VIRO Stock